Defence Therapeutics to Showcase Accum Platform at Key International Industry Events in March
Montreal, Quebec–(Newsfile Corp. – March 2, 2026) – Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) (“Defence” or the “Company”), a publicly traded biotechnology company advancing next-generation therapeutics using its proprietary Accum® platform, today outlined its participation in a series of major international industry events taking place in March 2026.
These high-profile meetings will provide Defence with multiple opportunities to advance strategic partnerships, strengthen its global network, and further position Accum® as a differentiated intracellular delivery technology for antibody-drug conjugates (ADCs), radiopharmaceutical conjugates (RDCs), and other complex biologics.
BIO-Europe Spring: Primary Focus on Strategic Partnerships
Defence will participate in BIO-Europe Spring (March 23-26, Lisbon, Portugal), the premier global partnering event for the life sciences industry. At BIO-Europe, the Company will prioritize discussions with biopharmaceutical partners seeking to collaborate on enhancing the intracellular delivery and efficacy of their ADC programs using Accum®.
Defence will also attend DCAT Week (March 23-26, New York), where the Company will focus on strengthening its manufacturing strategy. During DCAT, Defence plans to meet with contract research and manufacturing partners to advance the robust and high-quality biomanufacturing of Accum®, a key operational objective for the Company. Defence has recently become a member of the Drug, Chemical & Associated Technologies Association (“DCAT”), reinforcing its commitment to ensuring the well-characterized, quality-controlled, and commercially ready production of Accum®.
Expanding U.S. Presence and Investor Engagement
In parallel, Defence will participate in the South Florida Life Sciences Showcase (March 24, Miami) and FII PRIORITY Miami (March 25-27), supporting the Company’s ongoing investor outreach and business development efforts in the United States. Defence has also recently joined BioFlorida, further strengthening its footprint within the Florida life sciences ecosystem.
“As we engage with partners and industry stakeholders across these key events, our priority is to build meaningful collaborations that support the continued growth and adoption of Accum®,” said Sébastien Plouffe, CEO of Defence Therapeutics. “By enabling more efficient intracellular delivery of complex biologics, Accum® has the potential to significantly enhance therapeutic performance and tolerability, positioning the platform as a game-changing solution in the ADC field.”. To explore partnering opportunities or schedule a meeting, please contact Defence Therapeutics at info@defencetherapeutics.com.
About Defence Therapeutics:
Defence Therapeutics is a publicly traded biotechnology company committed to making cancer treatment more effective and safer. Using its Accum® precision drug delivery platform, Defence is working to enhance the potency of ADCs and other complex biologics at lower doses, with the goal of reducing side effects and improving access to advanced therapies. By pursing cutting edge science, and collaborating with pharma and biotech partners, Defence strives to bring transformative therapies to patients who need them most. To learn more about Defence Therapeutics and explore partnering opportunities, please visit www.defencetherapeutics.com or contact info@defencetherapeutics.com.
Cautionary Statement Regarding “Forward-Looking” Information
This release includes certain statements that may be deemed “forward-looking statements”. All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company’s management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management’s beliefs, estimates or opinions, or other factors, should change.
Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release.
Anfield Energy Inc. VANCOUVER, British Columbia, March 02, 2026 (GLOBE NEWSWIRE) — Anfield Energy Inc. (TSX.V: AEC; NASDAQ: AEC; FRANKFURT: 0AD) (“Anfield” or the “Company”), announces that the shareholders of the Company considered and voted at the special meeting of shareholders held on February 27, 2026 (the “Special Meeting”) to approve Uranium Energy Corp. (“Uranium
Palantir Technologies (PLTR +0.92%) shares have advanced 2,000% since January 2023, recording triple-digit returns in each of the last three years. But the stock has trended lower in 2026. It currently trades 34% below its record high despite the company reporting strong financial results in early February. However, Wall Street analysts covering Palantir generally think
Kaldalón hf. During week 9 of 2026, Kaldalón hf. did not purchase any shares under the share buyback programme announced on the stock exchange on 6 January 2026 Under the programme, Kaldalón may repurchase up to a maximum of 9,000,000 shares, provided that the total consideration paid does not exceed ISK 250,000,000. The execution of
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. If you are wondering whether EZCORP is still good value after its recent run, the key question is how its current share price compares with
For starters, let’s define what we mean by “emerging markets”. Emerging markets are developing economies (e.g., China, India, Brazil) as opposed to developed economies (e.g., Canada, Japan, the UK). Emerging markets are known for having cheap labor and producing products much less expensive than what they would cost if built in the U.S. When
China Stock Market Iran Conflict Impact on Stocks – The China-Global South Project MRKET REUTERS/Aly Song/File Photo China’s equity benchmarks were little changed on Monday in the wake of the Iran conflict as surges in energy, defense and gold stocks offset plunges in airline and tourism shares. Mainland sentiment was supported by expectations Beijing may
Packaged foods company B&G Foods (NYSE:BGS) will be reporting earnings this Tuesday afternoon. Here’s what investors should know. B&G Foods met analysts’ revenue expectations last quarter, reporting revenues of $439.3 million, down 4.7% year on year. It was a strong quarter for the company, with a beat of analysts’ EPS estimates and a solid beat
U.S. Stock Market indexes S&P 500, Nasdaq, and Dow Jones are heading for a volatile Monday as US-Iran war and Nvidia-AI worries will have big impact at the Wall Street on March 2. U.S. Stock futures were down in the pre-market on Sunday. S&P 500 futures were down by 0.43 per cent, Dow 30 futures
It’s difficult to imagine a stock surging after a failed acquisition. But that is exactly what happened with Netflix (NFLX +14.03%) last Friday. Shares of the streaming specialist jumped nearly 14% after the company officially walked away from its $83 billion bid for Warner Bros. Discovery‘s (WBD 2.24%) studio and streaming assets. For months, investors
Thick plumes of smoke rise over the residential areas of the Iranian capital following airstrikes amid ongoing U.S.â”Israel attacks as multiple explosions are heard across the city in Tehran, Iran on March 01, 2026. Fatemeh Bahrami/ | Anadolu | Getty Images We hear it all the time on CNBC — markets hate uncertainty, and the
New research from Bank of America (BAC 4.98%) shows that international stocks might be poised to outperform American equities. According to Bloomberg reporting, a new BofA report showed that international developed market stock funds have received $104 billion of new investment inflows so far this year, while U.S. stock funds have only received $25 billion.
Investors are bracing for the weekend attacks on Iran to ripple through markets. Front and center is the oil market, and the looming threat to energy flows. The Strait of Hormuz is among the world’s most important global shipping lanes, with 13 million barrels of crude oil per day flowing through the waterway in 2025,
JERUSALEM – FEBRUARY 28: People take shelter as Iran launched missiles and drones towards Israel following the US-Israeli attacks, in Jerusalem on February 28, 2026. Mostafa Alkharouf | Anadolu | Getty Images The U.S. and Israel launched their most aggressive attack ever on Iranian targets over the weekend that killed the Islamic state’s longtime supreme
Business The S&P 500 fell 29.98 points to 6,878.88. The Dow Jones Industrial Average dropped 521.28 to 48,977.92, and the Nasdaq composite sank 210.17 to 22,668.21. Currency traders watch monitors near a screen showing the Korea Composite Stock Price Index (KOSPI), top center, and the foreign exchange rate between U.S. dollar and South Korean won,
Although stock market volatility has been a common theme under President Donald Trump, Wall Street’s major indexes have thrived during his time in the Oval Office. In his first, non-consecutive term, the ageless Dow Jones Industrial Average (DJINDICES: ^DJI), benchmark S&P 500 (SNPINDEX: ^GSPC), and innovation-inspired Nasdaq Composite (NASDAQINDEX: ^IXIC) gained 57%, 70%, and 142%,
If you’re concerned about economic volatility, you’re in good company. In fact, 72% of Americans rate current economic conditions as “fair” or “poor,” according to a February 2026 survey from the Pew Research Center, while nearly 40% expect the economy to worsen over the next year. While the future of the economy may be largely
February was a wild month for the stock market as pressure built on software stocks over fears of AI disruption, and stocks fell in the last week of the month as President Trump said he would raise global tariffs to 15% after the Supreme Court struck down his earlier round of tariffs. Market pullbacks can
Over the last few years, just a handful of companies have come to dominate the market. Eleven stocks now trade on U.S. exchanges with market caps exceeding $1 trillion, as of this writing. Analysts expect the trend of the big getting bigger to continue in 2026, with price targets for most of the members of
This weekend, Berkshire Hathaway (NYSE: BRKA) (NYSE: BRKB) released its full-year financial report, and it contained a final warning from former CEO Warren Buffett, who retired in December. Berkshire was a net seller of stock in the fourth quarter, meaning it sold more stock than it purchased. The company has now been a net seller
Many investors aren’t quite sure how to feel about the market right now. According to a February 2026 survey from the American Association of Individual Investors, around 35% feel optimistic about the next six months, 37% feel pessimistic, and the remaining 28% feel neutral. So if you’re having mixed feelings about investing, you’re not alone.
